Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c01434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Mengqi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry…. Hauptthemen laut MEDLINE: Urea, Antineoplastic Agents, Imidazoles, Apoptosis. Die Arbeit nennt 63 Literaturangaben. Gefördert von: Central Plains Scholars and Scientists Studio Fund, Henan Key Laboratory of Organic Functional Molecules and Drug Innovation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Extracellular signal-regulated kinases (ERKs) are pivotal signaling molecules in the RAS-RAF-MEK-ERK signaling pathway and have emerged as potential antitumor targets, providing a promising strategy for tumor therapy. Therefore, the development of antitumor drugs targeting ERK protein has received extensive attention. Here, we developed a compound library based on a series of novel aromatic urea-imidazole salt derivatives and conducted phenotypic screening against various cancer cell lines. Notably, 21y exhibited high efficacy against MCF-7 cells (IC50 = 0.67 μM). Furthermore, label-free drug affinity responsive target stability (DARTS) and LC-MS/MS proteomics techniques revealed that 21y directly targets ERK1/2. Mechanistically, 21y induced cell apoptosis and autophagy-related cell death. In vivo studies confirmed that 21y strongly inhibited tumor growth and lung metastasis in breast cancer. Taken together, 21y targets ERK1/2 as a promising therapeutic agent for breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 45…
ORCID-Profile: Junbiao Chang, Bo Zhu
Förderung
- Central Plains Scholars and Scientists Studio Fund
- Henan Key Laboratory of Organic Functional Molecules and Drug Innovation
- National Natural Science Foundation of China
- Science and Technology Major Project of Henan Province
- Research Project from Pingyuan Laboratory
Zitieren
APA
Wang, M., Yang, S., Li, X., Zheng, Y., Bai, Y., Luo, W., Zhu, G., Chang, J., & Zhu, B. (2025). Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01434
Vancouver
Wang M, Yang S, Li X, Zheng Y, Bai Y, Luo W, et al. Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01434
BibTeX
@article{Wang2025,
author = {Wang, Mengqi and Yang, Shuping and Li, Xinge and Zheng, Yingying and Bai, Yan and Luo, Wenhan and Zhu, Gongming and Chang, Junbiao and Zhu, Bo},
title = {Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c01434}
}
EUVIMED